Thank you

This live web event has ended. Thank you for attending.

Description

"Progress in Amyloidosis: 2022"

Dr. Zonder will describe recent advances in the management of AL amyloidosis; review approved therapies for ATTR amyloidosis and how they work, and discuss new classes of agents designed to help remove existing amyloid deposits.

Presented by Jeffrey Zonder, MD, who is a Professor in the Departments of Oncology at the Barbara Ann Karmanos Cancer Institute (KCI) and Wayne State University School of Medicine. He is the Leader of the KCI Multiple Myeloma and Amyloidosis Multidisciplinary Team and Co-Leader of Molecular Therapeutics Program. He is a member of the Steering Committee of the Multiple Myeloma Research Consortium, a medical advisor for the Amyloidosis Support Groups Networks. Dr. Zonder is a member of the International Myeloma Working Group, the International Myeloma Society and the International Society of Amyloidosis. He is a member of the Southwest Oncology Group’s (SWOG) Barlogie-Salmon Myeloma Committee. Dr. Zonder has authored or co-authored numerous original research papers, review articles, book chapters, and research abstracts on myeloma and amyloidosis.

He completed a fellowship in hematology-oncology at Wayne State University and his medical residency at the University of Rochester, New York. He received his medical degree from Wayne State University School of Medicine.